Drugs / IBI188
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT04861948 | May 2021 → Jul 2022 | lung adenocarcinoma, osteosarcoma | Innovent Biologics (Suzhou) Co. Ltd. | Terminated | No outcome recorded |
| Phase 1 | NCT04485065 | Sep 2020 → Dec 2023 | myelodysplastic syndrome | Innovent Biologics (Suzhou) Co. Ltd. | Suspended | No outcome recorded Stop: Business |
| Phase 1 | NCT04511975 | Aug 2020 → Oct 2021 | myelodysplastic syndrome | Innovent Biologics (Suzhou) Co. Ltd. | Suspended | No outcome recorded |
| Phase 1 | NCT03763149 | Feb 2019 → Mar 2021 | cancer | Innovent Biologics (Suzhou) Co. Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT03717103 | Jan 2019 → Feb 2022 | cancer | Innovent Biologics (Suzhou) Co. Ltd. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04485052 | Sep 2020 → Jun 2024 | acute myeloid leukemia | Innovent Biologics (Suzhou) Co. Ltd. | Suspended | No outcome recorded Stop: Business |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2022-12-11 | Innovent Biologics (Suzhou) Co. Ltd. | Results Innovent Presents Phase 1b Clinical Data of IBI188 (Anti-CD47 Monoclonal Antibody) at the 2022 American Society of Hematology Annual Meeting innoventbio.com ↗
The Objective Response Rate (ORR) was 100% (30/30), complete response rate (CRR) was 63.3% (19/30). |
| 2020-11-11 | Innovent Biologics (Suzhou) Co. Ltd. | Results Innovent Releases Phase 1a Results of CD47 monoclonal antibody (Letaplimab) in monotherapy for advanced malignancies at SITC 2020 innoventbio.com ↗
As of June 18, 2020, letaplimab completed all the preset doses (maximum dose was 30mg/kg QW) without dose-limiting toxicity and was well tolerated in general. |
| 2018-09-10 | Innovent Biologics (Suzhou) Co. Ltd. | Regulatory Innovent's Anti-CD47 Antibody IBI188 Receives IND Approval in China innoventbio.com ↗
Innovent Biologics (Innovent), a world-class China-based biopharmaceutical company that develops and commercializes high quality drugs, today announced that its IND application for IBI188, a fully human anti-CD47 monoclonal antibody (mAb) drug candidate, has been approved by the National Medical Products Administration (NMPA, formerly known as CFDA) for clinical trials. |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2022-12-11 | Innovent Biologics (Suzhou) Co. Ltd. | Innovent Presents Phase 1b Clinical Data of IBI188 (Anti-CD47 Monoclonal Antibody) at the 2022 American Society of Hematology Annual Meeting innoventbio.com ↗ |
| 2020-11-11 | Innovent Biologics (Suzhou) Co. Ltd. | Innovent Releases Phase 1a Results of CD47 monoclonal antibody (Letaplimab) in monotherapy for advanced malignancies at SITC 2020 innoventbio.com ↗ |
| 2018-09-10 | Innovent Biologics (Suzhou) Co. Ltd. | Innovent's Anti-CD47 Antibody IBI188 Receives IND Approval in China innoventbio.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IBI188 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04511975 ↗ |
| Known as | LETAPLIMAB | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594553 ↗ |
| Modality | Monoclonal antibody | “Recombinant Human Anti-cluster Differentiation Antigen 47 (CD47) Monoclonal Antibody Injection (IBI188)” NCT03717103 ↗ |
| Route | Intravenous | “0.1 mg/kg IV QW” NCT03717103 ↗ |
| Target | CD47 | “Anti-cluster Differentiation Antigen 47 (CD47) Monoclonal Antibody” NCT03717103 ↗ |